ArticleFrontiers in immunology2022

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.

Xiaoling Shang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.